GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tourmaline Bio Inc (NAS:TRML) » Definitions » 3-Year EBITDA Growth Rate

Tourmaline Bio (Tourmaline Bio) 3-Year EBITDA Growth Rate : 0.00% (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Tourmaline Bio 3-Year EBITDA Growth Rate?

Tourmaline Bio's EBITDA per Share for the three months ended in Mar. 2024 was $-0.73.

During the past 12 months, Tourmaline Bio's average EBITDA Per Share Growth Rate was -507.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Competitive Comparison of Tourmaline Bio's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Tourmaline Bio's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tourmaline Bio's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tourmaline Bio's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Tourmaline Bio's 3-Year EBITDA Growth Rate falls into.


Tourmaline Bio 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Tourmaline Bio  (NAS:TRML) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Tourmaline Bio 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Tourmaline Bio's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Tourmaline Bio (Tourmaline Bio) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tourmaline Bio Inc (NAS:TRML) » Definitions » 3-Year EBITDA Growth Rate
Comparable Companies
CYTK NUVL KRYS CRSP INSM FOLD BPMC IMGN AXSM ACAD OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
27 West 24th Street, Suite 702, New York, NY, USA, 10010
Website
https://www.tourmalinebio.com
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.